News

The disposable NeuroCap allows for minimal chances of flawed EEG due to all of the contact points between scalp and electrode sensors being pre-gelled.

The chief scientific officer of the Parkinson’s Foundation also talked about the recent PD Health @ Home series created by the foundation.

Researchers found that, in an exploratory analysis of 150 patients, African American patients with MS were most likely to become disabled and lose employment.

In a study of more than 600 patients, single medication classes were overused by 70% of patients, and less than half of the cohort was taking a preventive treatment.

The chair of the Department of Neurology and the director of the Neuroscience Research Institute at The Ohio State University also offered his insight on discontinuing treatment in progressive MS.

Ishu Arpan, PhD, senior research associate at Oregon Health & Science University, discussed her team’s investigations into identifying patients with MS at risk of falling.

Increases in reperfusion treatment were the largest in lowest-volume hospitals, among rural residents, and among patients aged 85 years and older.

The director of the Lou Ruvo Center for Brain Health and neurologist at Cleveland Clinic provided an overview on how lenalidomide, an FDA-approved cancer drug, will be evaluated in Alzheimer disease.

Here's what is coming soon to NeurologyLive.

The 2-stage study is an open-label, 2-stage clinical trial designed to evaluate safety and dose-escalation (stage 1) and safety and efficacy (stage 2) of surgically delivered AXO-AAV-GM2.

The duo from Montefiore Medical Center discussed new modifications to the 2017 International League Against Epilepsy (ILAE) classification of seizures and epilepsies, relevant to neonates.

Patients having a relapse, confirmed disability accumulation, or worsening in fatigue had significant negative impact on each of the work productivity and activity impairment measures.

The neurologist from Massachusetts General Hospital discussed physician rationales behind prescribing DMT use in RIS.

Researchers found that the percentage of telemedicine visits increased from 15% to 72.8% during the COVID-19 pandemic.

Researchers found that higher NIHSS scores on admission and a successful first-pass effect were predictors of reaching early neurological improvement.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending March 5, 2021.

The president of the Americas Committee for Treatment and Research in MS discusses his takeaways from this year’s virtual forum.

At 18-month follow-up, 70% of those with an advanced Alzheimer disease pattern had 1 point or more increase in CDR-SB, an event predefined as clinically meaningful deterioration.

The assistant professor of neurology at Thomas Jefferson University discussed areas of poststroke care that need improvement including a more streamlined process.

The assistant professor of neurology at Mayo Clinic discussed his presented talk at ACTRIMS Forum 2021 on autoimmune encephalitis.

The duo from Cleveland Clinic discussed the reasons for choosing cycling as part of their newly initiated clinical trial, as well as what has been observed for home-based exercise interventions.

Researchers also found that patients with progressive MS had longer disease duration before starting DMTs than those with relapsing MS.

Genetically-index TNF-TNFR1 signaling blockade predicted reduced risk of Crohn disease and ulcerative colitis, and increased multiple sclerosis risk.

The director of research analytics at Cure SMA discussed her research on the economic burden and costs patients with spinal muscular atrophy and their caregivers face.

Researchers used single-cell RNA sequencing on adult, pediatric, and infant surgical tissues to study oligodendrocyte types in order to better understand multiple sclerosis.

Protalix BioTherapeutics intends to report final data on the agent, also known as PRX-102 in the second half of 2021, as well as present those findings at an appropriate medical conference.

The fellow of autoimmune neurology at Massachusetts General Hospital discusses the ongoing question about whether the demyelination is an unmasking of disease or consequence of the treatment.

Additionally, the therapy’s developer Yumanity Therapeutics announced the results of a single ascending dose study and enrollment in a multiple ascending dose study.

Avadel’s investigational therapy for excessive daytime sleepiness and cataplexy in narcolepsy has an action date set for October 15, 2021.

The PhD candidate at the neuroimmunology laboratory at Memorial University of Newfoundland discussed her team’s investigations into the use of IL-1RA as a biomarker for MS disability.